Emergent BioSolutions Inc（EBS）股票分析EBSEmergent BioSolutions Inc

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Emergent BioSolutions Inc (EBS) is currently not a strong buy due to its low current price of $6.23 and a concerning RSI of 31.437, indicating oversold conditions. While the recent surge in vaccine stock interest due to the Russian plague scare could provide some upside potential, the company faces significant risks, including a substantial net loss of $180.2 million in Q2 2026 and insider selling activity increasing by 140.86%.

6 analysts cover EBS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 15.00.